The Dysregulation of PARP9 Expression is Linked to Apoptosis and DNA Damage in Gastric Cancer Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Dec 31

PMID 39739965

Authors

Yating Li

Xing Wang

Xiaolong Liu

Xiangjie Li

Jianling Zhang

Yulan Li

Affiliations

Soon will be listed here.

Abstract

Background: Gastric cancer (GC) is a highly malignant gastrointestinal tumor characterized by difficult early diagnosis and poor prognosis. Therefore, it is imperative to explore potential therapeutic targets for gastric cancer. PARP9 is abnormally expressed in a variety of tumors and is associated with tumor cell apoptosis and DNA damage. However, its relationship with GC has not been fully studied.

Methods: The expression and prognostic significance of PARP9 in gastric cancer (GC) were examined using bioinformatics approaches. Cell lines with either knockdown or overexpression of PARP9 were established through lentiviral transduction, and the role of PARP9 in the malignant phenotypes of GC cells was validated via CCK8 assays, wound healing assays, clonogenic assays, and Transwell migration experiments. Finally, alterations in downstream targets and signaling pathways following changes in PARP9 expression were analyzed through RNA sequencing.

Results: PARP9 is highly expressed in GC tissues and is associated with poor prognosis. PARP9 knockdown can significantly inhibit the proliferation, invasion and migration of GC cells, and increase the apoptosis and DNA damage of GC cells. The therapeutic process of PARP9 in GC may be realized by synergistic interaction with SOX6 through MAPK signaling pathway.

Conclusions: Our study reveals a potential link between PARP9 and GC, providing a new target for the treatment of GC.

References

Tarazona N, Gimeno-Valiente F, Gambardella V, Huerta M, Rosello S, Zuniga S . Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. ESMO Open. 2020; 5(5):e000847. PMC: 7513635. DOI: 10.1136/esmoopen-2020-000847. View

Qi F, Wang Y, Yu B, Li F . Identification of RECK as a protective prognostic indicator and a tumor suppressor through regulation of the ERK/MAPK signaling pathway in gastric cancer. J Transl Med. 2023; 21(1):766. PMC: 10614389. DOI: 10.1186/s12967-023-04644-z. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Shen K, Yang L, Li F, Zhang F, Ding L, Yang J . Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer. Curr Drug Targets. 2021; 23(2):145-155. DOI: 10.2174/1389450122666210617111304. View

Luscher B, Ahel I, Altmeyer M, Ashworth A, Bai P, Chang P . ADP-ribosyltransferases, an update on function and nomenclature. FEBS J. 2021; 289(23):7399-7410. PMC: 9027952. DOI: 10.1111/febs.16142. View

Bourlon M, Valdez P, Castro E . Development of PARP inhibitors in advanced prostate cancer. Ther Adv Med Oncol. 2024; 16:17588359231221337. PMC: 10777773. DOI: 10.1177/17588359231221337. View

Lin Y, Zheng Y, Wang H, Wu J . Global Patterns and Trends in Gastric Cancer Incidence Rates (1988-2012) and Predictions to 2030. Gastroenterology. 2021; 161(1):116-127.e8. DOI: 10.1053/j.gastro.2021.03.023. View

Yousefi B, Mohammadlou M, Abdollahi M, Salek Farrokhi A, Karbalaei M, Keikha M . Epigenetic changes in gastric cancer induction by Helicobacter pylori. J Cell Physiol. 2019; 234(12):21770-21784. DOI: 10.1002/jcp.28925. View

Grimm D, Bauer J, Wise P, Kruger M, Simonsen U, Wehland M . The role of SOX family members in solid tumours and metastasis. Semin Cancer Biol. 2019; 67(Pt 1):122-153. DOI: 10.1016/j.semcancer.2019.03.004. View

10.

Tao L, Wang X, Zhou Q . Long noncoding RNA SNHG16 promotes the tumorigenicity of cervical cancer cells by recruiting transcriptional factor SPI1 to upregulate PARP9. Cell Biol Int. 2019; 44(3):773-784. DOI: 10.1002/cbin.11272. View

11.

Plummer M, Franceschi S, Vignat J, Forman D, de Martel C . Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2014; 136(2):487-90. DOI: 10.1002/ijc.28999. View

12.

Zamani M, Ebrahimtabar F, Zamani V, Miller W, Alizadeh-Navaei R, Shokri-Shirvani J . Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018; 47(7):868-876. DOI: 10.1111/apt.14561. View

13.

Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J . SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways. Exp Mol Med. 2023; 55(8):1757-1769. PMC: 10474099. DOI: 10.1038/s12276-023-01062-5. View

14.

Dang Y, Liu T, Yan J, Reinhardt J, Yin C, Ye F . Corrigendum to "Gastric cancer proliferation and invasion is reduced by macrocalyxin C via activation of the miR-212-3p/Sox6 pathway" [Cellular Signalling. 66 (2020) 109430]. Cell Signal. 2024; 121:111244. DOI: 10.1016/j.cellsig.2024.111244. View

15.

Dulaney C, Marcrom S, Stanley J, Yang E . Poly(ADP-ribose) polymerase activity and inhibition in cancer. Semin Cell Dev Biol. 2017; 63:144-153. DOI: 10.1016/j.semcdb.2017.01.007. View

16.

Huang H, Han Q, Zheng H, Liu M, Shi S, Zhang T . MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death Dis. 2021; 13(1):13. PMC: 8688448. DOI: 10.1038/s41419-021-04474-1. View

17.

Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong N . Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol. 2021; 14(1):51. PMC: 8008655. DOI: 10.1186/s13045-021-01061-x. View

18.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

19.

Kamachi Y, Kondoh H . Sox proteins: regulators of cell fate specification and differentiation. Development. 2013; 140(20):4129-44. DOI: 10.1242/dev.091793. View

20.

Chan C, Tan K, Cornelissen B . PARP Inhibitors in Cancer Diagnosis and Therapy. Clin Cancer Res. 2020; 27(6):1585-1594. DOI: 10.1158/1078-0432.CCR-20-2766. View